ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
테노포비르 디소프록실 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.3%를 나타내 46억 1,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 장시간 작용형 테노포비르 제제에 대한 수요 증가, 신규 항바이러스제와의 병용요법에 대한 주목 증가, 신규 테노포비르 병용요법에 대한 규제 당국의 승인 증가, 테노포비르의 소아용 제제에 대한 주목 증가, 노출 후 예방에 있어서의 테노포비르 수요 증가에 기인합니다. 예측 기간의 주요 동향으로는 신규 약물전달 시스템의 개발, 의약품 개발에 있어서의 인공지능의 통합, 병용 요법의 진보, 나노 테크놀로지를 이용한 딜리버리의 진보, 합제 요법의 진보 등을 들 수 있습니다.
향후 5년간의 성장률 5.3%라고 하는 예측은 이 시장의 전회 예측으로부터 0.3%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 인도나 아일랜드에서 제조되는 뉴클레오티드 역전사효소 억제제, 노출 전 예방제, 노출 후 예방제의 가격을 늘리고 HIV 예방·치료 비용을 상승시키기 때문에 미국의 HIV 클리닉을 저해할 가능성이 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
HIV와 에이즈의 유병률 증가는 테노포비르 디소프록실 시장 성장을 가속할 것으로 예측됩니다. HIV와 AIDS는 CD4 세포를 공격하여 면역계를 약화시키고 신체를 감염과 질병에 걸리기 쉽게 만드는 만성 바이러스 감염입니다. 이러한 질병의 유병률 증가는 무방비 성적 접촉, 인식 부족, 건강 관리 접근 제한, 약물 내성 바이러스 균주의 출현 등의 요인 때문입니다. HIV/AIDS 환자가 증가함에 따라 치료 및 예방에 사용되는 주요 항-레트로바이러스 약물인 테노포비르 디소프록실 수요가 증가하고 있습니다. 예를 들어, 2024년 7월 스위스에 본부를 둔 정부기관인 유엔합동 에이즈 계획(UNAIDS)은 2022년 말까지 세계에서 약 3,950만명이 HIV에 감염되었고 같은 해 약 130만명의 신규 감염이 기록되었다고 보고했습니다. 게다가 2022년에는 에이즈 관련 질환에 의한 사망자가 세계에서 약 63만 명 발생했고, 2023년에는 HIV와 함께 사는 사람의 수는 3,990만명(3,610만 명-4,460만 명)으로 증가했습니다. 그 결과 HIV와 에이즈의 유병률 증가가 테노포비르 디소프록실 시장 성장에 박차를 가하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 테노포비르 디소프록실 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 테노포비르 디소프록실 시장 : 성장률 분석
세계의 테노포비르 디소프록실 시장 실적 : 규모와 성장(2019-2024년)
세계의 테노포비르 디소프록실 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 테노포비르 디소프록실 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 테노포비르 디소프록실 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
정제
분말
세계의 테노포비르 디소프록실 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
온라인 약국
소매 약국
도매업체 또는 유통업체
세계의 테노포비르 디소프록실 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
세계의 테노포비르 디소프록실 시장 : 정제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일 약물 정제
고정 용량 복합 정제
세계의 테노포비르 디소프록실 시장 : 분말 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구용 분말
재구성 가능 분말
제7장 지역별/국가별 분석
세계의 테노포비르 디소프록실 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 테노포비르 디소프록실 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
테노포비르 디소프록실 시장 : 경쟁 구도
테노포비르 디소프록실 시장 : 기업 프로파일
Gilead Sciences Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Viatris Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Teva Pharmaceuticals Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
Cipla Ltd : 개요, 제품 및 서비스, 전략 및 재무 분석
Lupin Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Mylan NV
Blanver
SMS Pharmaceuticals
Bajaj Healthcare
Mangalam Drugs & Organics Ltd
Nortec Quimica
Arene Lifesciences
Cdymax
HRV Global Life Sciences
Pipelinepharma
Qilu Pharmaceutical
Jai Radhe Sales
Sinoway Industrial Co. Ltd
Aurisco Pharmaceutical
Huangshi Fuertai Pharmaceutical Tech Co. Ltd
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
테노포비르 디소프록실 시장(2029년) : 새로운 기회를 제공하는 국가
테노포비르 디소프록실 시장(2029년) : 새로운 기회를 제공하는 부문
테노포비르 디소프록실 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Tenofovir disoproxil is a medication used for treating HIV-1 infection and chronic hepatitis B. As a prodrug of tenofovir, it converts into its active form in the body, inhibiting viral replication. It belongs to the nucleotide reverse transcriptase inhibitors (NRTIs) class, which blocks a crucial enzyme required for viral multiplication.
The primary forms of tenofovir disoproxil are tablets and powder. Tablets are solid medicinal forms designed for easy swallowing, dissolving in the digestive system to release the active ingredient either gradually or immediately. The medication is distributed through online pharmacies, retail pharmacies, and wholesalers or distributors, with applications primarily in hospitals and clinics.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The tenofovir disoproxil market research report is one of a series of new reports from The Business Research Company that provides tenofovir disoproxil market statistics, including the tenofovir disoproxil industry's global market size, regional shares, competitors with a tenofovir disoproxil market share, detailed tenofovir disoproxil market segments, market trends and opportunities, and any further data you may need to thrive in the tenofovir disoproxil industry. This tenofovir disoproxil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The tenofovir disoproxil market size has grown steadily in recent years. It will grow from $3.58 billion in 2024 to $3.76 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to the growth in awareness and early detection of viral infections, rising cases of hepatitis b infections, expansion of generic drug manufacturing for tenofovir disoproxil, rising number of clinical trials supporting tenofovir efficacy, and growth in healthcare funding for infectious disease treatment.
The tenofovir disoproxil market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to the rising demand for long-acting tenofovir formulations, increasing focus on combination therapies with newer antivirals, rising regulatory approvals for novel tenofovir combinations, rising focus on pediatric formulations of tenofovir, and increasing demand for tenofovir in post-exposure prophylaxis. Major trends in the forecast period include development of novel drug delivery systems, integration of artificial intelligence in drug development, advancements in combination therapies, advancements in nanotechnology-based delivery, and advancements in fixed-dose combination therapies.
The forecast of 5.3% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers may hamper U.S. HIV clinics by inflating prices of nucleotide reverse transcriptase inhibitors and pre-exposure prophylaxis and post-exposure prophylaxis formulations manufactured in India and Ireland, elevating HIV prevention and treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of HIV and AIDS is expected to drive the growth of the tenofovir disoproxil market. HIV and AIDS are chronic viral infections that weaken the immune system by attacking CD4 cells, making the body more susceptible to infections and diseases. The rising prevalence of these conditions is attributed to factors such as unprotected sexual contact, lack of awareness, limited access to healthcare, and the emergence of drug-resistant virus strains. The growing number of HIV and AIDS cases is increasing the demand for tenofovir disoproxil, a key antiretroviral drug used for treatment and prevention. For example, in July 2024, the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, reported that by the end of 2022, approximately 39.5 million people were living with HIV worldwide, with about 1.3 million new infections recorded that year. Additionally, in 2022, around 630,000 deaths from AIDS-related illnesses occurred globally, with the number of people living with HIV rising to 39.9 million (36.1 million-44.6 million) in 2023. As a result, the increasing prevalence of HIV and AIDS is fueling the growth of the tenofovir disoproxil market.
The growing prevalence of hepatitis B is also expected to contribute to the expansion of the tenofovir disoproxil market. Hepatitis B is a viral infection that targets the liver and can lead to both acute and chronic disease, transmitted through contact with infected blood or bodily fluids. Factors such as perinatal transmission, unsafe medical practices, lack of vaccination coverage, and the persistence of chronic infections in affected populations are driving the rise in hepatitis B cases. Tenofovir disoproxil is a widely used treatment for chronic hepatitis B, helping to suppress viral replication and minimize liver damage. For instance, in March 2023, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, estimated that between 580,000 and 2.4 million people in the United States are living with hepatitis B infection, with about two-thirds potentially unaware of their condition. Consequently, the increasing prevalence of hepatitis B is contributing to the demand for tenofovir disoproxil.
Leading companies in the tenofovir disoproxil market are focusing on innovative formulations, such as combination therapies, to enhance HIV/AIDS treatment and maintain a competitive edge. Combination therapy involves the simultaneous use of two or more treatments to improve therapeutic outcomes and patient well-being. For instance, in July 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus (HBV) infection in pediatric patients aged six years and older, weighing at least 25 kg, with compensated liver disease. The FDA's approval was based on data from a Phase II clinical trial demonstrating the drug's safety and efficacy in children as young as six years old.
Major players in the tenofovir disoproxil market are Gilead Sciences Inc., Viatris Inc., Teva Pharmaceuticals Limited, Cipla Ltd, Lupin Limited, Mylan NV, Blanver, SMS Pharmaceuticals, Bajaj Healthcare, Mangalam Drugs & Organics Ltd, Nortec Quimica, Arene Lifesciences, Cdymax, HRV Global Life Sciences, Pipelinepharma, Qilu Pharmaceutical, Jai Radhe Sales, Sinoway Industrial Co. Ltd, Aurisco Pharmaceutical, Huangshi Fuertai Pharmaceutical Tech Co. Ltd.
North America was the largest region in the tenofovir disoproxil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tenofovir disoproxil report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the tenofovir disoproxil market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tenofovir disoproxil market consists of sales of active pharmaceutical ingredients (APIs), branded formulations, generic formulations, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tenofovir Disoproxil Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on tenofovir disoproxil market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for tenofovir disoproxil ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tenofovir disoproxil market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Tablet; Powder
2) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Wholesalers Or Distributors
3) By Application: Hospital; Clinic
Subsegments:
1) By Tablet: Single-Drug Tablets; Fixed-Dose Combination Tablets
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Tenofovir Disoproxil Market Characteristics
3. Tenofovir Disoproxil Market Trends And Strategies
4. Tenofovir Disoproxil Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Tenofovir Disoproxil Growth Analysis And Strategic Analysis Framework
5.1. Global Tenofovir Disoproxil PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Tenofovir Disoproxil Market Growth Rate Analysis
5.4. Global Tenofovir Disoproxil Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Tenofovir Disoproxil Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Tenofovir Disoproxil Total Addressable Market (TAM)
6. Tenofovir Disoproxil Market Segmentation
6.1. Global Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablet
Powder
6.2. Global Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Online Pharmacies
Retail Pharmacies
Wholesalers Or Distributors
6.3. Global Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Clinic
6.4. Global Tenofovir Disoproxil Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-Drug Tablets
Fixed-Dose Combination Tablets
6.5. Global Tenofovir Disoproxil Market, Sub-Segmentation Of Powder, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Powder
Reconstitutable Powder
7. Tenofovir Disoproxil Market Regional And Country Analysis
7.1. Global Tenofovir Disoproxil Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Tenofovir Disoproxil Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
